Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to observed prospectively the efficacy and safety of 6 months and long-term treatment of Tacrolimus alone or with methotrexate (MTX) in moderate and severe Chinese RA patients who shown insufficiency response or intolerance to DMARDs
This study will enroll 150 cases of refractory rheumatoid arthritis (RA) patients in Chinese，who are in moderate or severe disease activity and insufficiency response or intolerance to DMARDs. The participants plan to be treated with Tacrolimus alone, or along with methotrexate (MTX) if participants were tolerant to MTX. The efficacy and safety of 6 month Tacrolimus treatment in RA patients will be evaluated with DAS28 and other disease activity indices.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tacrolimus group | Experimental | RA patients treated with tacrolimus, without MTX |
|
| Tacrolimus + MTX group | Active Comparator | RA patients treated with tacrolimus and MTX |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tacrolimus | Drug | Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline Disease Activity Score 28 (DAS28-ESR) at 24 and longer weeks. | Change from baseline Disease Activity Score 28 (DAS28) erythrocyte sedimentation rate (ESR) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline ACR20 response rate at 24 and longer weeks. | Change from baseline ACR20 response rate at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| The clinical remission rate at 24 and longer weeks. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Qiang Shu, Dr. | Qilu Hospital of Shandong University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qilu Hospital | Jinan | Shandong | 250012 | China |
De-identified individual participant data for all primary and secondary outcome measures will be made available within 12 months of study completion.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016559 | Tacrolimus |
| D008727 | Methotrexate |
| ID | Term |
|---|---|
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D000630 | Aminopterin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| MTX | Drug | MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops. |
|
|
The percentage of patients who achieve clinical remission patients at the endpoint or withdraw timepoint.
High disease activity: DAS28 score exceeding 5.1, Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1, Low disease activity (LDA): DAS28 score of less than or equal to 3.2, Remission: DAS28 score is less than 2.6. clinical remission means Low disease activity or remission.
| 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Clinical response was analyzed using the European League Against Rheumatism (EULAR) improvement criteria. | Good response: ΔDAS28 > 1.2 and DAS28 ≤3.2； Moderate response: 1.2 ≥ΔDAS28 > 0.6 and 3.2<DAS28 ≤5.1； or ΔDAS28 > 1.2 and still DAS28>3.2； No response:ΔDAS28≤0.6； or 1.2≥ΔDAS28 > 0.6 and DAS28>5.1。 | 12 week,3 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline Simplified Disease Activity Index (SDAI) at 24 and longer weeks. | Change from baseline Simplified Disease Activity Index (SDAI) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline Clinical disease activity index (CDAI) at 24 and longer weeks. | Change from baseline Clinical disease activity index (CDAI) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline Erythrocyte Sedimentation Rate (ESR) at 24 and longer weeks. | Change from baseline Erythrocyte Sedimentation Rate (ESR) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline C-Reactive Protein (CRP) at 24 and longer weeks. | Change from baseline C-Reactive Protein (CRP) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline swollen joint number (SW28) at 24 and longer weeks. | Change from baseline swollen joint number (SW28) at 24 and longer weeks. SW28 means the number of joints with swelling counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline tenderness joint number (T28) at 24 and longer weeks. | Change from baseline tenderness joint number (T28) at 24 and longer weeks. T28 means the number of joints with tenderness upon touching counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline patient global assessment(PGA) at 24 and longer weeks. | Change from baseline patient global assessment(PGA) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline physician global assessment(PHGA) at 24 and longer weeks. | Change from baseline physician global assessment(PHGA) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Change from baseline Health Assessment Questionnaire (HAQ) at 24 and longer weeks. | Change from baseline Health Assessment Questionnaire (HAQ) at 24 and longer weeks. | 12 week, 24week,36 week,48 week,72 week,96 week,120 week,144 week |
| Safety assessed by Adverse Events (AEs) | An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product | Up to 144 weeks |
| Safety assessed by incidence of serious adverse events (SAE) | Adverse Event is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event. | Up to 144 weeks |
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D011622 |
| Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |